Trial reportOpen forum infectious diseases2025
Oritavancin for the Treatment of
Trial report in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Optimizing Treatment of Infective Endocarditis in Patients Who Inject Drugs.Antibiotics (Basel, Switzerland) · 2026Review
- Off-label use of oritavancin: a case series on clinical effectiveness, bed-day savings and cost benefits.JAC-antimicrobial resistance · 2026Article
- Oritavancin for Gram-Positive Bone and Joint Infections: A Comprehensive Review of the Literature.Antibiotics (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Patients who require prolonged intravenous antibiotics for Objectives: To assess the outcomes, including safety and impact on length of stay and cost-effectiveness of using oritavancin for patients with SAB who are ineligible for OPAT. Methods: Retrospective single-arm cohort study of adult patients with SAB who received at least 1 dose of oritavancin within the Hunter New England Local Health District between January 2020 and July 2023. Results: A total of 27 patients were identified: mean age, 43 years, 52% male, and 59% people who currently inject drugs. Sources/foci of infection included bone/joint infection (26%), skin/soft-tissue infection (15%), infective endocarditis (26%), catheter-associated bacteremia (7%), and bacteremia with no clear source/focus (26%). Intravenous antibiotics were administered for a mean duration of 10 days before oritavancin therapy. Clinical cure was seen in 26/27 (96%) of patients, with 1 patient lost to follow-up and deemed not clinically evaluable. Twenty-four of 27 (89%) patients were alive at the end of the 180-day follow-up period, with 2 patient deaths unrelated to their index infection and 1 patient not clinically evaluable. A total of 89% of patients demonstrated a positive return on investment, with on average 18 hospital days per patient avoided. Conclusions: Oritavancin is promising as a suitable and potentially cost-effective alternative for patients with SAB who are ineligible for OPAT. Prospective studies are required to confirm its utility in clinical practice, in particular in patients who do not receive oral antibiotic stepdown therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.